Topic: Multaq
(Reuters) - U.S. regulators on Monday revised the label for Sanofi SA's heart drug Multaq to reflect a doubling of health risks, including death, for some patients with irregular heart rhythms.In the updated label, the Food and Drug Administration said Multaq, known ...
Nov. 19--CHICAGO -- A heart drug that was the subject of a Journal Sentinel investigative report earlier this year has been linked to an increasing number of adverse side effects, according to an analysis by a watchdog group that monitors medication errors ...
If you have a life threatening heart arrhythmia, Multaq is one of the drugs which doctors may use in order to get the heart beating normally again. Under some cases, your doctor may not be able to use Multaq. If you are ...
STOCKHOLM (Reuters) - Sanofi-Aventis's recently launched heart rhythm drug Multaq should be considered as a treatment option for patients with atrial fibrillation, a common arrhythmia, according to new medical guidelines.Multaq, or dronedarone, was designed as a improvement on the older drug amiodarone. ...
SNY) announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)[1] for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for the management of patients with ...
Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 This is an essential source of information and analysis on the global atrial fibrillation market. The report identifies the key trends shaping and driving the market, and provides insight on the ...
The Food and Drug Administration has approved Multaq 400 mg tablets to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter. Multaq is an anti-arrhythmic indicated to reduce the risk of cardiovascular hospitalization in patients ...
Sanofi-Aventis (SNY) finally received some good news when the U.S. FDA approved the company's heart drug, Multaq, on July 2, 2009. The approval process for Multaq was not exactly smooth sailing with the company receiving a non-approvable letter from the FDA for ...
The Food and Drug Administration has approved Multaq 400 mg tablets to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter. Multaq is an anti-arrhythmic indicated to reduce the risk of cardiovascular hospitalization in patients ...
Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing approval from the Food and Drug Administration, which turned it down three years ago.Multaq is intended to treat atrial flutter and atrial fibrillation, related heart disorders in which ...
